Intravesical administration of radiolabelled tumour-associated monoclonal antibody in bladder cancer.
Considerable progress has been made over the past decade in the use of tumour-associated monoclonal antibodies (mAbs) as carriers of cytotoxic agents in the management of several malignancies. In the present study we investigated the tumour localization and biodistribution of the mAb HMFG1 to bladder cancer following intravesical administration. HMFG1, which has been raised against the polymorphic epithelial mucin (PEM), was labelled with 125I and administered intravesically 2 h and 24 h before cystoscopy. During cystoscopy, biopsies were taken from the normal bladder and the malignant lesion. Tissue samples were tested for HMFG1 immunostaining and for radioactivity with the use of a gamma-counter. The mean ratio of tumour to normal uptake for 125I-HMFG1 was 5.81 +/- 1.23, at 2 h and 2.17 +/- 0.42 at 24 h. No radioactivity was detected in the blood. We conclude that HMFG1 could be used intravesically for the successful delivery of a cytotoxic agent.
Syrigos
K N
KN
Department of Clinical Oncology, Imperial College of Science, Technology and Medicine, Hammersmith Hospital Campus, London, England.
Khawaja
M
M
Krausz
T
T
Williams
G
G
Epenetos
A A
AA
D000283:Administration, Intravesical; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D018396:Mucin-1 / Q000276:immunology*; D016499:Radioimmunotherapy; D014018:Tissue Distribution; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy*
D000911:Antibodies, Monoclonal; D018396:Mucin-1